news about Advancis Pharmaceutical To Present At NYSSA Biotech/Specialty Pharma Conference

Advancis Pharmaceutical To Present At NYSSA Biotech/Specialty Pharma Conference

2005/12/07

Advancis Pharmaceutical Corporation (Nasdaq: AVNC - News), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that Dr. Edward M. Rudnic, Advancis chairman, president and CEO, will deliver a corporate presentation on Wednesday, December 14, 2005, at 12:00 noon Eastern Time.

The presentation will take place as part of the New York Society of Security Analysts (NYSSA) Ninth Annual Biotech/Specialty Pharma Industry Conference at the Harvard Club in New York, NY. Dr. Rudnic's remarks will be available live on the Advancis web site, where they also will be archived for 30 days.

To access the presentation, log on to http://www.advancispharm.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

About NYSSA(investment industry):

NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,000 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 131 societies worldwide that make up CFA Institute, which has more than 70,000 members. Continue to learn more about investment industry, please visit Investment Service.

About Advancis Pharmaceutical:

Advancis Pharmaceutical Corporation (Nasdaq: AVNC - News) is a pharmaceutical company focused on the development and commercialization of pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS. By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products.

About Advancis

Fighting bacteria with more effective products.

Advancis™ is a forward-thinking company built on a foundation of extensive pharmaceutical knowledge.

Founded in 1999, Advancis has discovered a novel biological finding with the potential to fundamentally advance the way we fight bacteria.

Our mission, based on this proprietary discovery, is to develop and commercialize value-added pharmaceuticals for the anti-infectives market.

A strategy based on proprietary advancements and solid partnerships.

Advancis?? commercial strategy is to develop and commercialize products both independently and in partnership with other pharmaceutical companies.

The strength of our offerings is protected by the 43 patents we have filed for our proprietary technologies and formulations.

These advancements have the potential to improve antiviral and antifungal therapies as well as antibiotic treatments, extending our market.

Advancis™ is prepared to meet the demand for improved anti-infectives.

Since its first big boom in the 1940s, the anti-infectives market has been growing rapidly. In 2002, worldwide sales of all anti-infective drugs totaled approximately $44.7 billion, with antibiotic sales alone comprising about $27.2 billion.

This expansion shows no signs of slowing. The demand for anti-infectives continues to grow as bacterial resistance builds.

In spite of the ready market, however, few advancements have been made in overcoming significant insufficiencies:

• Lack of drugs formulated for once-daily dosing
• Limited efficacy of treatments for patients with resistant infections
• Detrimental side effects of existing treatments
• Lengthy courses of therapy
• Lack of formulation alternatives for IV/oral administration

Continue to learn more about investment industry, please visit Advancis.

Home | Investment Management | Investment Bank | Foreign Investment | Investment Funds | Investment Company | Investment Services | Investment Industry

Copyright © 2005 Investment Service. All Rights Reserved.